When immunotherapy stops holding the line against kidney cancer, patients need another playbook that still fits daily life.
On Sept. 24, the FDA approved belzutifan (Welireg, Merck) plus lenvatinib (Lenvima, Eisai) for adults with advanced renal cell carcinoma (RCC) that has a clear-cell component after treatment with a PD-1 or PD-L1 inhibitor — including disease that progressed during or after that therapy, or within six months of finishing adjuvant PD-1 treatment.
Approval rests on the Phase 3 LITESPARK-011 trial of 747 patients randomized to the combination or to cabozantinib alone. Median progression-free survival was 14.6 months with Welireg plus Lenvima versus 10.6 months with cabozantinib (hazard ratio 0.74). Overall survival at the final analysis was not statistically significant, though the combination arm’s median OS was numerically longer (33.7 vs 28.6 months).
Both drugs carry serious labeled risks — including a boxed warning on belzutifan for embryo-fetal toxicity, plus anemia and hypoxia warnings; lenvatinib’s label lists hypertension and other significant toxicities — and the combo adds cardiac-dysfunction precautions. The recommended dose is 120 mg belzutifan plus 20 mg lenvatinib orally once daily until progression or unacceptable toxicity.
Why regular people should care
Clear-cell kidney cancer is one of the more common kidney cancers in adults. After checkpoint inhibitors, many people still need another option that does not mean living at an infusion chair. Two pills with a proven delay in progression versus a standard next drug is a concrete win for patients and caregivers navigating “what’s next?” — always with a clinician reading the full safety picture.
What’s next
Watch how quickly oncologists adopt the combo after PD-1/PD-L1 failure, how side effects are managed in practice, and whether longer follow-up clarifies the survival story. For patients in that gap, a new dual oral regimen is now on the table.